Skip to main content
. 2015 Jan 27;4(1):e224. doi: 10.1038/mtna.2014.75

Figure 3.

Figure 3

FX lead short interfering RNAs (siRNAs) demonstrate in vivo selectivity as well as potency. New Zealand White rabbits received a single administration of vehicle, or nt control siRNA-LNP (1 mg/kg), or FX:(335) siRNA-LNP or FX:(336) siRNA-LNP (0.1 or 1 mg/kg) at day 0 (n = 3 per group). Hepatic mRNA levels of FX and other coagulation factors were determined at day 7. Individual animals and group means with standard deviations are shown. **P < 0.01, ***P < 0.001 compared to nt control.